Optimal condition of heparin-conjugated fibrin with bone morphogenetic protein-2 for spinal fusion in a rabbit model

Jae-Young Hong, Sun Woong Kang, Jung Wook Kim, Seung-Woo Suh, You Jin Ko, Jung-Ho Park

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background aims: Heparin-conjugated fibrin (HCF) is a carrier for long-term release of bone morphogenetic protein-2 (BMP-2) and has been shown to promote bone formation in animal models. We performed an experimental study to determine the optimal dose of BMP-2 with an HCF carrier that promotes bone formation comparable to that of autograft while minimizing complications in spinal fusion. Methods: Twenty-four rabbits underwent posterolateral fusion of the L5-6 spinal segments. Different concentrations of HCF BMP-2 (1/10, 1/20, 1/30 or 1/40) were implanted in the spines of experimental rabbits, and autograft or INFUSE was implanted in the spines of control animals. Eight weeks after treatment, spinal fusion efficacy was evaluated by plain radiography, micro-computed tomography (micro-CT), mechanical testing and histomorphometry. Results: Similar to autograft, the 1/40 HCF BMP-2 showed significant bone formation on micro-CT and histomorphometry with mechanical stability. However, the other HCF BMP-2 concentrations did not show significant bone formation compared with autograft. Although conventional BMP-2 (INFUSE) led to higher bone formation and stability, it also led to excessive ectopic bone and fibrous tissue formation. Conclusions: This study suggests the optimal concentration of BMP-2 using HCF for spinal fusion, which may decrease the complications of high-dose conventional BMP-2.

Original languageEnglish
Pages (from-to)1441-1448
Number of pages8
JournalCytotherapy
Volume16
Issue number10
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Bone Morphogenetic Protein 2
Spinal Fusion
Fibrin
Heparin
Rabbits
Osteogenesis
Autografts
Bone Morphogenetic Protein 1
Spine
Tomography
Radiography
Animal Models
Bone and Bones

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Oncology
  • Genetics(clinical)
  • Transplantation
  • Cancer Research
  • Cell Biology

Cite this

Optimal condition of heparin-conjugated fibrin with bone morphogenetic protein-2 for spinal fusion in a rabbit model. / Hong, Jae-Young; Kang, Sun Woong; Kim, Jung Wook; Suh, Seung-Woo; Ko, You Jin; Park, Jung-Ho.

In: Cytotherapy, Vol. 16, No. 10, 01.01.2014, p. 1441-1448.

Research output: Contribution to journalArticle

@article{376bb747a17046fba2d595df574fe985,
title = "Optimal condition of heparin-conjugated fibrin with bone morphogenetic protein-2 for spinal fusion in a rabbit model",
abstract = "Background aims: Heparin-conjugated fibrin (HCF) is a carrier for long-term release of bone morphogenetic protein-2 (BMP-2) and has been shown to promote bone formation in animal models. We performed an experimental study to determine the optimal dose of BMP-2 with an HCF carrier that promotes bone formation comparable to that of autograft while minimizing complications in spinal fusion. Methods: Twenty-four rabbits underwent posterolateral fusion of the L5-6 spinal segments. Different concentrations of HCF BMP-2 (1/10, 1/20, 1/30 or 1/40) were implanted in the spines of experimental rabbits, and autograft or INFUSE was implanted in the spines of control animals. Eight weeks after treatment, spinal fusion efficacy was evaluated by plain radiography, micro-computed tomography (micro-CT), mechanical testing and histomorphometry. Results: Similar to autograft, the 1/40 HCF BMP-2 showed significant bone formation on micro-CT and histomorphometry with mechanical stability. However, the other HCF BMP-2 concentrations did not show significant bone formation compared with autograft. Although conventional BMP-2 (INFUSE) led to higher bone formation and stability, it also led to excessive ectopic bone and fibrous tissue formation. Conclusions: This study suggests the optimal concentration of BMP-2 using HCF for spinal fusion, which may decrease the complications of high-dose conventional BMP-2.",
keywords = "Autograft, BMP-2, Heparin-conjugated fibrin, Spinal fusion",
author = "Jae-Young Hong and Kang, {Sun Woong} and Kim, {Jung Wook} and Seung-Woo Suh and Ko, {You Jin} and Jung-Ho Park",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jcyt.2014.04.005",
language = "English",
volume = "16",
pages = "1441--1448",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Optimal condition of heparin-conjugated fibrin with bone morphogenetic protein-2 for spinal fusion in a rabbit model

AU - Hong, Jae-Young

AU - Kang, Sun Woong

AU - Kim, Jung Wook

AU - Suh, Seung-Woo

AU - Ko, You Jin

AU - Park, Jung-Ho

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background aims: Heparin-conjugated fibrin (HCF) is a carrier for long-term release of bone morphogenetic protein-2 (BMP-2) and has been shown to promote bone formation in animal models. We performed an experimental study to determine the optimal dose of BMP-2 with an HCF carrier that promotes bone formation comparable to that of autograft while minimizing complications in spinal fusion. Methods: Twenty-four rabbits underwent posterolateral fusion of the L5-6 spinal segments. Different concentrations of HCF BMP-2 (1/10, 1/20, 1/30 or 1/40) were implanted in the spines of experimental rabbits, and autograft or INFUSE was implanted in the spines of control animals. Eight weeks after treatment, spinal fusion efficacy was evaluated by plain radiography, micro-computed tomography (micro-CT), mechanical testing and histomorphometry. Results: Similar to autograft, the 1/40 HCF BMP-2 showed significant bone formation on micro-CT and histomorphometry with mechanical stability. However, the other HCF BMP-2 concentrations did not show significant bone formation compared with autograft. Although conventional BMP-2 (INFUSE) led to higher bone formation and stability, it also led to excessive ectopic bone and fibrous tissue formation. Conclusions: This study suggests the optimal concentration of BMP-2 using HCF for spinal fusion, which may decrease the complications of high-dose conventional BMP-2.

AB - Background aims: Heparin-conjugated fibrin (HCF) is a carrier for long-term release of bone morphogenetic protein-2 (BMP-2) and has been shown to promote bone formation in animal models. We performed an experimental study to determine the optimal dose of BMP-2 with an HCF carrier that promotes bone formation comparable to that of autograft while minimizing complications in spinal fusion. Methods: Twenty-four rabbits underwent posterolateral fusion of the L5-6 spinal segments. Different concentrations of HCF BMP-2 (1/10, 1/20, 1/30 or 1/40) were implanted in the spines of experimental rabbits, and autograft or INFUSE was implanted in the spines of control animals. Eight weeks after treatment, spinal fusion efficacy was evaluated by plain radiography, micro-computed tomography (micro-CT), mechanical testing and histomorphometry. Results: Similar to autograft, the 1/40 HCF BMP-2 showed significant bone formation on micro-CT and histomorphometry with mechanical stability. However, the other HCF BMP-2 concentrations did not show significant bone formation compared with autograft. Although conventional BMP-2 (INFUSE) led to higher bone formation and stability, it also led to excessive ectopic bone and fibrous tissue formation. Conclusions: This study suggests the optimal concentration of BMP-2 using HCF for spinal fusion, which may decrease the complications of high-dose conventional BMP-2.

KW - Autograft

KW - BMP-2

KW - Heparin-conjugated fibrin

KW - Spinal fusion

UR - http://www.scopus.com/inward/record.url?scp=84908509079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908509079&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2014.04.005

DO - 10.1016/j.jcyt.2014.04.005

M3 - Article

C2 - 24934306

AN - SCOPUS:84908509079

VL - 16

SP - 1441

EP - 1448

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 10

ER -